Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy

Oncotarget

Volumn 7, Issue 9, 2016, Pages 10174-10181

  Martín Martín, Lourdes ^a   Almeida, Julia ^a   Pomares, Helena ^b   González Barca, Eva ^b   Bravo, Pilar ^c   Giménez, Teresa ^d   Heras, Cecilia ^e   Queizán, José Antonio ^f   Pérez Ceballos, Elena ^g   Martínez, Violeta ^h   Alonso, Natalia ⁱ   Calvo, Carlota ^j   álvarez, Rodolfo ^k   Caballero, María Dolores ^l   Orfao, Alberto ^a  

^a Centro de Investigacion del Cancer   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^d HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^e HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^f Nephrology Section Hospital of Segovia   (Spain)

^g HOSPITAL MORALES MESEGUER   (Spain)

^h Gastroenterology Unit Hospital of Leon   (Spain)

ⁱ University Hospital of Santiago de Compostela   (Spain)

^j HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^k HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^l HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

more..

Author keywords

ALL therapy; Blastic plasmacytoid dendritic cell neoplasm; Central nervous system; Flow cytometry; Intrathecal prophylaxis

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; HYDROCORTISONE; METHOTREXATE; PREDNISONE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; BONE MARROW TUMOR; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM TUMOR; CHEMOPROPHYLAXIS; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MIDDLE AGED; OCCULT CANCER; OVERALL SURVIVAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SCHOOL CHILD; VERY ELDERLY; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM NEOPLASMS; DENDRITIC CELL; HEMATOLOGIC NEOPLASMS; MORTALITY; PATHOLOGY; SECONDARY; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; DENDRITIC CELLS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84961658194     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7101     Document Type: Article

References (22)

1. Martin-Martin L, Lopez A, Vidriales B, Caballero MD, Rodrigues AS, Ferreira SI, Lima M, Almeida S, Valverde B, Martinez P, Ferrer A, Candeias J, Ruiz-Cabello F, Buadesa JM, Sempere A, Villamor N, et al. Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget. 2015; 6:19204-19216. doi: 10.18632/oncotarget.4146
2. Feuillard J, Jacob MC, Valensi F, Maynadie M, Gressin R, Chaperot L, Arnoulet C, Brignole-Baudouin F, Drenou B, Duchayne E, Falkenrodt A, Garand R, Homolle E, Husson B, Kuhlein E, Le Calvez G, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002; 99:1556-1563
3. Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, Lunghi M, Pica G, Onida F, Cattaneo C, Piccaluga PP, Di Bona E, Todisco E, Musto P, Spadea A, D'Arco A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013; 98:239-246
4. Tsagarakis NJ, Kentrou NA, Papadimitriou KA, Pagoni M, Kokkini G, Papadaki H, Pappa V, Marinakis T, Anagnostopoulos NI, Vadikolia C, Anagnostopoulos A, Angelopoulou MK, Terpos E, Poziopoulos C, Anargyrou K, Rontogianni D, et al. Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res. 2010; 34:438-446
5. Hashikawa K, Niino D, Yasumoto S, Nakama T, Kiyasu J, Sato K, Kimura Y, Takeuchi M, Sugita Y, Hashimoto T and Ohshima K. Clinicopathological features and prognostic significance of CXCL12 in blastic plasmacytoid dendritic cell neoplasm. J Am Acad Dermatol. 2012; 66:278-291
6. Pemmaraju N, Kantarjian HM, Cortes JE, Duvic M, Khoury JD, Patel K, Daver N, O'Brien S, Pierce S, Garcia-Manero G, Jabbour E, Jain N, Faderl S, Thomas D, Frankel AE, Qazilbash MH, et al. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes. Blood. 2015; 126:3746-3746
7. Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K, Taguchi J, Kondo T, Ohata K, Ito T, Kamoda Y, Fukuda T, Ichinohe T, Takeuchi K, Izutsu K and Suzumiya J. Longterm survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015; 125:3559-3562
8. Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Iriondo Atienza A, Arcese W, Beelen DW, Cornelissen JJ, Kroger N, Milone G, Rossi G, Jardin F, Peters C, Rocha V, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013; 121:440-446
9. Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS and Jaffe ES. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010; 95:1873-1879
10. Facchetti F, Jones M and Petrella T. (2008). Blastic plasmacytoid dendritic cell neoplasm. In: Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H et al., ed. WHO classification of tumors of hematopoietic and lymphoid tissues. (Lyon, France: International Agency for Research on Cancer (IARC)), pp. 145-147
11. Rees JK, Gray RG, Swirsky D and Hayhoe FG. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet. 1986; 2:1236-1241
12. Quijano S, Lopez A, Manuel Sancho J, Panizo C, Deben G, Castilla C, Antonio Garcia-Vela J, Salar A, Alonso-Vence N, Gonzalez-Barca E, Penalver FJ, Plaza-Villa J, Morado M, Garcia-Marco J, Arias J, Briones J, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009; 27:1462-1469
13. Bromberg JE, Breems DA, Kraan J, Bikker G, van der Holt B, Smitt PS, van den Bent MJ, van't Veer M and Gratama JW. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology. 2007; 68:1674-1679
14. Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, Dunleavy K, Jaffe ES, Abati A, Stetler-Stevenson M and Wilson WH. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005; 105:496-502
15. Pistoia V and Raffaghello L. Disclosing the mysteries of the central nervous system sanctuary for acute lymphoblastic leukemia cells. Leuk Res. 2011; 35:699-700
16. Aoki J, Ishiyama K, Taniguchi S, Fukuda T, Ohashi K, Ogawa H, Kanamori H, Eto T, Iwato K, Sakamaki H, Morishima Y, Nagamura T, Atsuta Y and Takami A. Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement. Biol Blood Marrow Transplant. 2014; 20:2029-2033
17. Leclerc M, Peffault de Latour R, Michallet M, Blaise D, Chevallier P, Rohrlich P-S, Turlure P, Nguyen S, Jardin F, Yakoub-Agha I, Moukhtari L, Raus N and Maury S. Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Retrospective Study of the French Society of Bone Marrow Transplantation and Cell Therapy (SFGMTC). Blood. 2015; 126:3208-3208
18. Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M and Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014; 124:385-392
19. Sweet KL, Pemmaraju N, Lane AA, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Rowinsky EK, Szarek M, Brooks CL, Disalvatore S, Liu D, Duvic M, Schwartz JD and Konopleva M. Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML). Blood. 2015; 126:3795-3795
20. Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, Salaun V, Garand R, Lepelley P, Maynadie M, Kuhlein E, Deconinck E, Daliphard S, Chaperot L, Beseggio L, Foisseaud V, et al. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. British journal of haematology. 2009; 145:624-636
21. Ribera JM, Ortega JJ, Oriol A, Bastida P, Calvo C, Perez-Hurtado JM, Gonzalez-Valentin ME, Martin-Reina V, Molines A, Ortega-Rivas F, Moreno MJ, Rivas C, Egurbide I, Heras I, Poderos C, Martinez-Revuelta E, et al. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial. J Clin Oncol. 2007; 25:16-24
22. van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J, Rawstron A, Asnafi V, Lecrevisse Q, Lucio P, Mejstrikova E, Szczepanski T, Kalina T, de Tute R, Bruggemann M, Sedek L, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012; 26:1908-1975